Allopurinol and Radiation Therapy
Allopurinol is indicated during radiation therapy primarily for prevention and treatment of tumor lysis syndrome (TLS) in patients with malignancies at risk of rapid cell turnover, not as a routine adjunct to radiation itself. The key context is managing hyperuricemia from tumor cell destruction, which can occur with radiation treatment of bulky tumors or when combined with chemotherapy.
Primary Indication
Allopurinol prevents uric acid formation in patients undergoing cancer treatment (including radiation therapy) who are at risk for TLS. For low-risk patients receiving radiation therapy, allopurinol combined with hydration is the appropriate prophylactic approach 1. High-risk patients should receive rasburicase instead, particularly those with preexisting hyperuricemia ≥7.5 mg/dL 2.
Risk Stratification
Before initiating allopurinol, assess TLS risk based on:
- Disease factors: Bulky disease (especially small cell lung cancer with massive liver metastases), high-grade lymphomas, elevated LDH >2× upper normal limit 1
- Host factors: Pre-existing renal impairment, hyperuricemia, dehydration 1
- Treatment factors: Intensive therapy including radiation combined with chemotherapy 1
Obtain baseline creatinine clearance, LDH, and renal ultrasound before starting prophylaxis 1.
Dosing Regimen
Standard Dosing
Administer allopurinol orally at 100 mg/m² three times daily (maximum 800 mg/day) or 10 mg/kg/day divided every 8 hours 2. For adults unable to take oral medication, IV dosing is 200-400 mg/m²/day in 1-3 divided doses (maximum 600 mg/day) 2.
Timing
- Start 1-2 days before radiation/chemotherapy initiation 2
- Continue for 3-7 days after treatment based on ongoing TLS risk 2
- Use a low starting dose (100 mg daily) and escalate weekly by 100 mg to minimize hypersensitivity risk 3
Critical Dose Adjustments
Renal impairment requires mandatory dose reduction 2:
- CrCl 10-20 mL/min: 200 mg daily maximum
- CrCl <10 mL/min: 100 mg daily maximum
- CrCl <3 mL/min: Extend dosing intervals 3
When co-administered with 6-mercaptopurine or azathioprine, reduce these agents by 65-75% 2 due to allopurinol's inhibition of their metabolism.
Monitoring Recommendations
High-Risk Patients
Monitor every 12 hours for first 3 days, then every 24 hours 1:
- Serum uric acid
- Electrolytes (potassium, phosphate, calcium)
- Renal function (creatinine, BUN)
- LDH
Patients with Established TLS
Monitor every 6 hours for first 24 hours 1:
- Vital signs (heart rate, blood pressure, urine output, respiratory rate)
- All laboratory parameters above
- Urine pH and specific gravity (maintain at 1.010)
Safety Monitoring
Discontinue allopurinol immediately at first appearance of skin rash, which may herald severe hypersensitivity reactions including Stevens-Johnson syndrome 3. Monitor liver function tests in patients with pre-existing liver disease 3.
Essential Supportive Measures
Vigorous hydration is mandatory: Maintain urine output ≥100 mL/hour in adults (3 mL/kg/hour in children <10 kg) 1. Fluid intake should yield ≥2 liters daily urinary output 3.
Urine alkalinization may be considered for low-risk patients on allopurinol alone, but do NOT alkalinize urine if rasburicase is used concurrently 1.
Critical Drug Interactions
Monitor and adjust doses of 2:
- Dicumarol
- Thiazide diuretics (increased hypersensitivity risk with renal impairment) 3
- Chlorpropamide
- Cyclosporine
- Cyclophosphamide and other cytotoxic agents
Important Caveats
- Allopurinol only prevents NEW uric acid formation—it does not reduce pre-existing hyperuricemia 2. Patients with baseline uric acid ≥7.5 mg/dL should receive rasburicase instead 2.
- Risk of xanthine crystalluria exists due to accumulation of less soluble xanthine metabolites; adequate hydration mitigates this 2.
- Gout flares may paradoxically increase during early allopurinol therapy; prophylactic colchicine is recommended 3.
- Do NOT co-administer allopurinol with rasburicase to avoid xanthine accumulation and substrate depletion 1.